Polyvalent Binding and Avidity
Affinity is the binding strength of a single ligand to a single receptor. Avidity is the collective binding strength of multiple ligands simultaneously engaging multiple receptors. Avidity can be orders of magnitude higher than affinity, and the mechanism is entropic.
When a bivalent ligand has one arm bound, the tethered second arm is confined to a hemisphere around the first binding site. Its effective local concentration (C_eff) is:
C_eff = 1000 / (N_A × 2/3 × π × r³)
At r = 39 Å: C_eff = 13.4 mM. If the Kd for the second binding event is 4 µM, then C_eff/Kd ≈ 3400. The second arm binds almost instantly after the first. The whole complex now dissociates 3400× slower than a monovalent ligand. That’s avidity.
The entropy logic: paying the translational/rotational entropy penalty (ΔG^s ~ 4-10 kcal/mol) once vs twice is the difference between tight and weak binding. Jencks 1981 established this framework; Kramer & Karpen 1998 demonstrated it empirically with PEG-cGMP dimers achieving 1000× potency over cGMP.
What determines the potency peak: the optimal linker length matches the distance between receptor binding sites on the target. Too short: second arm can’t reach the second site. Too long: C_eff drops because the hemisphere volume grows with r³. The relationship is:
- Potency ∝ C_eff ∝ 1/r³ ∝ 1/(MW_linker)^(3/2) for flexible polymers
Two mechanisms of polyvalent inhibition (Mammen 1998):
- Statistical rebinding: slow off-rate from simultaneous multi-site occupancy
- Steric stabilization: polymer chains physically block access to surface receptor arrays
Selectivity from polyvalency: different proteins with similar binding sites but different site spacings respond optimally to different linker lengths. Kramer & Karpen showed OLF channel (optimal 39 Å), RET channel (30 Å), and PKG (<20 Å) are distinguishable purely by PLD length. No structure required — just empirical screening.
For STRC therapeutic design: if mini-STRC fragments, peptide fragments of tectorin-binding domains, or stereocilin N-terminal repeats present paired binding sites, a PLD or polymer-displayed version could achieve nanomolar affinities from micromolar monovalent starters. This is the most underexplored design space for STRC molecular therapy.
Connections
[source]Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors**[source]Spanning binding sites on allosteric proteins with polymer-linked ligand dimers[about]Intrinsic Binding Energy and Connection Gibbs Energy[about]Polymer-Linked Ligand Dimer Strategy[applies]STRC Research Portal[see-also]STRC Gene Therapy sphere